NATCOPHARM

NATCO PHARMA

Mid Cap BSE: 524816 NSE: NATCOPHARM
₹750.5
0.7 (0.09%)
As on 09 August, 2022 | 16:13

Natco Pharma Share Price

Natco Pharma Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Natco Pharma Share Returns

  • Over 1 Month 17.28%
  • Over 3 Month -2.39%
  • Over 6 Month -17.59%
  • Over 1 Year -24.49%

Natco Pharma Key Statistics

P/E Ratio 98.6
PEG Ratio -1.8
Market Cap Cr 13,701
Price to Book Ratio 229.6
EPS 7.6
Dividend 225
Relative Strength Index 80.42
Money Flow Index 100
MACD Signal 14.04
Average True Range 21.35

Natco Pharma Investment Rating

  • Master Rating:
  • Natco Pharma has an operating revenue of Rs. 1,862.10 Cr. on a trailing 12-month basis. An annual revenue growth of 6% is not great, Pre-tax margin of 9% is okay, ROE of 3% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and around 12% up from its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 33 which is a POOR score indicating inconsistency in earnings, a RS Rating of 30 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 96 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Natco Pharma Financials
  • Indicator
  • Mar 2022
  • Dec 2021
  • Sep 2021
  • Jun 2021
  • Mar 2021
  • Oper Rev Qtr Cr
  • 514
  • 530
  • 330
  • 394
  • 312
  • Operating Expenses Qtr Cr
  • 552
  • 442
  • 281
  • 280
  • 235
  • Operating Profit Qtr Cr
  • -38
  • 88
  • 49
  • 114
  • 76
  • Depreciation Qtr Cr
  • 36
  • 36
  • 34
  • 33
  • 30
  • Interest Qtr Cr
  • 4
  • 4
  • 3
  • 2
  • 2
  • Tax Qtr Cr
  • -6
  • 8
  • -1
  • 16
  • 16
  • Net Profit Qtr Cr
  • -61
  • 72
  • 54
  • 75
  • 57

Natco Pharma Technicals

EMA & SMA

Current Price
750.5
0.7 (0.09%)
  • Bullish Moving Average
  • ___
  • 13
  • Bearish Moving Average
  • ___
  • 3
  • 20 Day
  • 696.9
  • 50 Day
  • 688.05
  • 100 Day
  • 717.03
  • 200 Day
  • 792.03
  • 20 Day
  • 680.41
  • 50 Day
  • 669.91
  • 100 Day
  • 716.51
  • 200 Day
  • 791.9

Natco Pharma Resistance and Support

PIVOT
₹751.84
Resistance
  • First Resistance
  • 759.97
  • Second Resistance
  • 770.14
  • Third Resistance
  • 778.27
Support
  • First Resistance
  • 741.67
  • Second Resistance
  • 733.54
  • Third Resistance
  • 723.37
  • RSI
  • 80.42
  • MFI
  • 100
  • MACD Single Line
  • 14.04
  • MACD
  • 24.94

Natco Pharma Delivery and Volume

  • Period
  • NSE + BSE
    Volume Avg
  • NSE + BSE
    Delivery Volume Avg
  • NSE + BSE
    Delivery Volume %
  • Day
  • 393,208
  • 23,848,065
  • 60.65
  • Week
  • 608,282
  • 34,738,974
  • 57.11
  • 1 Month
  • 303,421
  • 18,778,700
  • 61.89
  • 6 Month
  • 269,925
  • 15,822,985
  • 58.62

Natco Pharma Result Highlights

Natco Pharma Synopsis

NSE-Medical-Diversified

Natco Pharma is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1653.50 Cr. and Equity Capital is Rs. 36.50 Cr. for the Year ended 31/03/2021. Natco Pharma Ltd. is a Public Limited Listed company incorporated on 19/09/1981 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24230TG1981PLC003201 and registration number is 003201.
  • Market Cap
  • 13,701
  • Sales
  • 1,768
  • Shares in Float
  • 9.31
  • No of funds
  • 215
  • Yield
  • 0.6
  • Book Value
  • 3.27
  • U/D Vol ratio
  • 2.3
  • LTDebt / Equity
  • Alpha
  • -0.11
  • Beta
  • 0.64

Natco Pharma

  • Owner Name
  • Jun-22
  • Mar-22
  • Dec-21
  • Sep-21
  • Promoters
  • 48.8%
  • 48.81%
  • 48.86%
  • Mutual Funds
  • 6.75%
  • 7.39%
  • 9.07%
  • Foreign Portfolio Investors
  • 11.65%
  • 11.94%
  • 12.23%
  • Financial Institutions/ Banks
  • 0.16%
  • 0.16%
  • Individual Investors
  • 18.45%
  • 17.47%
  • 16.54%
  • Others
  • 14.35%
  • 14.23%
  • 13.14%

Natco Pharma Management

  • Name
  • Designation
  • Mr. V C Nannapaneni
  • Chairman & Managing Director
  • Mr. Rajeev Nannapaneni
  • Vice Chairman & CEO
  • Mr. T V Rao
  • Independent Director
  • Mr. G S Murthy
  • Independent Director
  • Mr. D G Prasad
  • Independent Director
  • Dr. M U R Naidu
  • Independent Director
  • Dr. Leela Digumarti
  • Independent Director
  • Mr. P S R K Prasad
  • Director & Exe. VP (Corp. Engg. Services)
  • Dr. Linga Rao Donthineni
  • Director & President (Tech. Affairs)
  • Mr. Sridhar Sankararaman
  • Non Exe.Non Ind.Director

Natco Pharma Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Natco Pharma Corporate Action

  • Date
  • Purpose
  • Remarks
  • 2022-08-09
  • Quarterly Results & Interim Dividend
  • 2022-05-30
  • Audited Results
  • 2022-02-14
  • Quarterly Results & 3rd Interim Dividend
  • 2021-11-11
  • Quarterly Results & Interim Dividend
  • 2021-08-12
  • Quarterly Results & Interim Dividend
  • Date
  • Purpose
  • Remarks
  • 2022-02-25
  • INTERIM
  • Rs.2.00 per share (100%) Third Interim Dividend
  • 2021-11-24
  • INTERIM
  • Re.0.50 per share (25%) Second Interim Dividend
  • 2021-08-25
  • INTERIM
  • Rs.2.00 per share(100%)Interim Dividend
  • 2021-02-23
  • INTERIM
  • Rs.1.00 per share (50%) Third Interim Dividend

Natco Pharma MF Shareholding

  • Name
  • Amount(cr)
  • ICICI Prudential Value Discovery Fund Growth
  • 23053
  • Mirae Asset Emerging Bluechip Fund Growth
  • 20664
  • Mirae Asset Midcap Fund Regular Growth
  • 7173
  • Sundaram Mid Cap Growth
  • 7156
  • SBI Magnum Midcap Fund Regular Growth
  • 6741

Natco Pharma FAQs

What is Share Price of Natco Pharma ?

Natco Pharma share price is ₹750 As on 09 August, 2022 | 15:59

What is the Market Cap of Natco Pharma ?

The Market Cap of Natco Pharma is ₹13700.9 Cr As on 09 August, 2022 | 15:59

What is the P/E ratio of Natco Pharma ?

The P/E ratio of Natco Pharma is 98.5 As on 09 August, 2022 | 15:59

What is the PB ratio of Natco Pharma ?

The PB ratio of Natco Pharma is 3.3 As on 09 August, 2022 | 15:59

Q1FY23